ConductScience.org, home
Papers
API referenceFor AI assistants

Paper · 28034880

Polyclonal Secondary FGFR2 Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion-Positive Cholangiocarcinoma.

Goyal L and 31 others. Cancer Discov, 2017. Cited by 471 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Download JSON
Cite this record

ConductScience Library. Polyclonal Secondary FGFR2 Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion-Positive Cholangiocarcinoma. Papers, record 28034880. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/28034880

On this page

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Polyclonal Secondary FGFR2 Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion-Positive Cholangiocarcinoma.
PubMed
Journal
Cancer Discov
PubMed
Year
2017
PubMed
Publication types
Case Reports, Journal Article
PubMed
Citations, by iCite
471
iCite
Relative citation ratio, by iCite
14.5
iCite
Revised in PubMed
2024-06-10
PubMed

Authors32

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Goyal LLipika
2Saha SKSupriya K
3Liu LYLeah Y
4Siravegna GGiulia
5Leshchiner IIgnaty
6Ahronian LGLeanne G
7Lennerz JKJochen K
8Vu PPhuong
9Deshpande VVikram
10Kambadakone AAvinash

1 to 10 of 32Source PubMed

See all 32 authors

Topics19

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Antineoplastic AgentsMajor topic
Bile Duct NeoplasmsMajor topic
CholangiocarcinomaMajor topic
Drug Resistance, NeoplasmMajor topic
Phenylurea CompoundsMajor topic
PyrimidinesMajor topic
Receptor, Fibroblast Growth Factor, Type 2Major topic
Adult
Cell Cycle Proteins
Circulating Tumor DNA
Female
Gene Fusion
Humans
Male
Membrane Transport Proteins
Middle Aged
Mutation
Receptor, Fibroblast Growth Factor, Type 3
Transcription Factor TFIIIA

Source PubMed

Grants5

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated bySource
K08 CA194268NCI NIH HHSUnited StatesK08CA194268PubMed and NIHNIH RePORTER
P50 GM107618NIGMS NIH HHSUnited StatesP50GM107618PubMedNIH RePORTER
R01 CA208437NCI NIH HHSUnited StatesR01CA208437PubMedNIH RePORTER
P50 CA127003NCI NIH HHSUnited StatesP50CA127003PubMed and NIHNIH RePORTER
K08 CA166510NCI NIH HHSUnited StatesK08CA166510PubMedNIH RePORTER

Trials2

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's recordSource
NCT07142226Role of ctDNA in Genetic Profiling & Outcomes for Advanced BTCBackgroundClinicalTrials.gov
NCT07151118ctDNA in Genetic Profiling and Clinical Outcomes of Advanced Biliary Tract CancerBackgroundClinicalTrials.gov

Comments and corrections1

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

KindPMIDTitleIn Papers
Comment in28,264,865Gatekeeper Mutations and Intratumoral Heterogeneity in FGFR2-Translocated Cholangiocarcinoma.https://conductscience.org/library/papers/28264865

Source PubMed

References42

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
124,142,049Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing.Nat Biotechnol2013https://conductscience.org/library/papers/24142049PubMed
224,122,810Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma.Hepatology2014https://conductscience.org/library/papers/24122810PubMed
326,452,027Prospective blinded study of somatic mutation detection in cell-free DNA utilizing a targeted 54-gene next generation sequencing panel in metastatic solid tumor patients.Oncotarget2015https://conductscience.org/library/papers/26452027PubMed
410,964,570T-Coffee: A novel method for fast and accurate multiple sequence alignment.J Mol Biol2000https://conductscience.org/library/papers/10964570PubMed
524,550,739Integrated genomic characterization reveals novel, therapeutically relevant drug targets in FGFR and EGFR pathways in sporadic intrahepatic cholangiocarcinoma.PLoS Genet2014https://conductscience.org/library/papers/24550739PubMed
626,474,073Analytical and Clinical Validation of a Digital Sequencing Panel for Quantitative, Highly Accurate Evaluation of Cell-Free Circulating Tumor DNA.PLoS One2015https://conductscience.org/library/papers/26474073PubMed
72,268,628WHAT IF: a molecular modeling and drug design program.J Mol Graph1990https://conductscience.org/library/papers/2268628PubMed
825,608,663Massive parallel sequencing uncovers actionable FGFR2-PPHLN1 fusion and ARAF mutations in intrahepatic cholangiocarcinoma.Nat Commun2015https://conductscience.org/library/papers/25608663PubMed
920,979,473EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors.N Engl J Med2010https://conductscience.org/library/papers/20979473PubMed
1021,697,284A drug resistance screen using a selective MET inhibitor reveals a spectrum of mutations that partially overlap with activating mutations found in cancer patients.Cancer Res2011https://conductscience.org/library/papers/21697284PubMed

1 to 10 of 42

See all 42 references

Cited by302

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 471 citations.

PMIDTitleJournalYearIn PapersSource
42,938,881Liquid Biopsy in Hepatobiliary and Pancreatic Malignancies: Current Evidence and Implications for Surgical Practice.Cancers (Basel)2026https://conductscience.org/library/papers/42938881PubMed
42,881,857
Molecularly Guided Therapy and the Tumor Microenvironment in Advanced Cholangiocarcinoma: Current Evidence and Emerging Strategies Targeting FGFR2, HER2, and IDH1 with Pemigatinib, Zanidatamab, and Ivosidenib.
J Clin Med2026https://conductscience.org/library/papers/42881857PubMed
42,732,071Characteristics of fusion genes in breast cancer.Cancer Cell Int2026https://conductscience.org/library/papers/42732071PubMed
42,703,482Landscape of acquired resistance alterations in gastrointestinal malignancies after genomically targeted therapy.J Gastrointest Oncol2026https://conductscience.org/library/papers/42703482PubMed
42,703,280Persistent FGFR pathway dependence: where does tinengotinib fit after FGFR inhibitor therapy in advanced cholangiocarcinoma?J Gastrointest Oncol2026https://conductscience.org/library/papers/42703280PubMed
42,679,332Sequencing of Fibroblast Growth Factor Receptor Inhibitors in Cholangiocarcinoma: A Review of Published Cases.JCO Precis Oncol2026https://conductscience.org/library/papers/42679332PubMed
42,675,086Discovery of a covalent FGFR2-selective inhibitor overcoming clinically-acquired resistance mutations.Nat Commun2026https://conductscience.org/library/papers/42675086PubMed
42,649,986Biological and Targeted Therapies in the Multidisciplinary Management of Gastrointestinal Cancers.Cancers (Basel)2026https://conductscience.org/library/papers/42649986PubMed
42,633,326Advances in FGF/FGFR Signaling: Implications for Disease and Therapy.MedComm (2020)2026https://conductscience.org/library/papers/42633326PubMed
42,621,139The role of FGFR signaling in SCLC and NSCLC: Current insights and therapeutic perspectives.iScience2026https://conductscience.org/library/papers/42621139PubMed

1 to 10 of 302

See all 302 cited by

Genes24

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
AHCYL110,768PubTator's text mininghttps://conductscience.org/library/genes/10768NCBI Gene
AKT1207PubTator's text mininghttps://conductscience.org/library/genes/207NCBI Gene
ALK238PubTator's text mininghttps://conductscience.org/library/genes/238NCBI Gene
ARID2196,528PubTator's text mininghttps://conductscience.org/library/genes/196528NCBI Gene
ATR545PubTator's text mininghttps://conductscience.org/library/genes/545NCBI Gene
BICC180,114PubTator's text mininghttps://conductscience.org/library/genes/80114NCBI Gene
BRAF673PubTator's text mininghttps://conductscience.org/library/genes/673NCBI Gene
COL17A11,308PubTator's text mininghttps://conductscience.org/library/genes/1308NCBI Gene
FBXW755,294PubTator's text mininghttps://conductscience.org/library/genes/55294NCBI Gene
FGFR12,260PubTator's text mininghttps://conductscience.org/library/genes/2260NCBI Gene

1 to 10 of 24

See all 24 genes

Drugs0

The drugs whose trials, in the Pipelines release, list the paper.

None in this release.

Data0

The data bank entries PubMed's record names. Trial numbers are under Trials.

None in this release.

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/28034880

GET https://conductscience.org/api/papers/v1/28034880/authors?page=2

API referenceFor AI assistants